P968 Influences of Sequential Introduction of Thiopurine on Long-Term Efficacy of Infliximab in Patients with Inflammatory Bowel Disease
C Zhang,P Zhang,R Mao,B Chen,Y He,Z Zeng,Y Qiu,M Chen
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1098
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background As one of the biological agents for the treatment of inflammatory bowel disease (IBD), infliximab (IFX) has gradually become a cornerstone drug over the past two decades. While there is still a non-negligible loss of response rate, which may be explained by immunogenicity. A coping method is adding immunomodulators, among which thiopurine (TP) is the most common choice. However, combination therapy may lead to an increased risk of infection and malignancy, and how to introduce immunosuppressive agents properly to maximize benefits remains a controversial dilemma. Therefore, this study aims to assess the impact of sequentially introducing TP on the long-term effectiveness of IBD patients receiving concurrent IFX treatment. Methods A retrospective analysis was conducted at a tertiary hospital between June 2013 and January 2022. Primary outcomes encompassed drug sustainability and biological switching. Multivariate analyses were employed to examine factors influencing these outcomes. Results Among 787 consecutive patients, 500 were included in the final analysis. Of these, 166 received IFX monotherapy and 334 were on IFX-TP cotherapy (173 were prior TP exposure, 59 initiating TP post 3 months of IFX treatment and 102 with de novo combination). A total of 152 (28.94%) patients discontinued the IFX regimen within 18.2 months. Additionally, 119 (22.67%) patients switched to alternative biologics within a median of 18.1 months, with higher switching rates in the monotherapy and early exposure groups (P = 0.027). Antibodies to infliximab (ATI) were detected in 36.7% patients within a median of 5 months. The monotherapy group exhibited higher cumulative rate of ATI development, ATI concentrations, and lower trough levels (TLs), while the de novo combination group demonstrated the lowest ATI development and highest TLs. Only the order of introduction of TP therapy (HR 0.698, 95%CI 0.597-0.815, P <0.001) and ATI formation (HR 1.009, 95%CI 1.003-1.014, P =0.004) were associated with drug sustainability. Both the de novo (HR 0.367, 95%CI 0.263-0.512, P <0.001) and the late combination group (HR 0.53, 95%CI 0.359-0.782, P =0.001) had relatively higher drug retention when compared to the others. In terms of biological switching, combination therapy (HR 0.41, 95%CI 0.19-0.88, P =0.023) and the order of introducing TPs had a significant effect (HR 0.391, 95%CI 0.183-0.836, P =0.015). Moreover, the de novo combination group demonstrated fewer clinical flares (P = 0.043). Conclusion Initiating TPs de novo may improve drug sustainability and offer better long-term efficacy for IBD patients receiving IFX therapy.
gastroenterology & hepatology